Novartis has announced today that the European Commission has approved Kymriah (tisagenlecleucel) for the treatment of acute lymphoblastic leukemia in children and adults up to 25 years of age.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,